Appoints Jonathan Burgin as Chief Financial Officer
Tel-Aviv, Israel – March 15, 2021 – Tarsier Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the appointment of Jonathan Burgin, MBA, as the new Chief Financial Officer of the company.
“Jonathan’s appointment comes at an intriguing time for Tarsier Pharma, as we grow the organization and advance our lead drug candidate TRS01 for uveitic glaucoma towards phase-III clinical trials, while continuing to develop transformative treatments based on our novel molecular platform to address inflammatory ocular diseases. Thanks to Jonathan’s expertise and leadership experience especially in financial roles, he will be instrumental in expediting our growth and commercial success,” stated Daphne Haim-Langford, PhD, CEO and Chairperson at Tarsier.
Jonathan Burgin is a seasoned C level Executive bringing with him over 20 years of managerial experience and leadership, including 16 years in life science companies. Most recently he served in the position of CFO and COO at Anchiano Therapeutics, a clinical stage biopharmaceutical company developing drugs against cancer (Nasdaq: ANCN), and is a board member of Cellect Biotechnology (Nasdaq: APOP), a cell therapy company. Jonathan has raised over $200 million in capital in support of advancing companies’ missions.
“This is a very exciting time to be joining Tarsier Pharma management team,” said Jonathan. “Having a solid business foundation, a growing pipeline, and as several key milestones are expected in the next year, I am looking forward to working together to achieve the Company’s next level of growth”.
About Tarsier Pharma
Tarsier Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.
The company’s investors include a wholly-owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.